Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Q4 Earnings Might Spell a Discount for TDOC Stock

By Josh Enomoto, InvestorPlace Contributor

The raging coronavirus outbreak bolsters the underlying business of TDOC stock. However, Q4 might pressure shares due to troubles justifying the rich premium.

7 Lessons Businesses Can Learn From the Girl Scouts

By Josh Enomoto, InvestorPlace Contributor

The Girl Scouts is one of America’s proudest traditions. It’s also a source of valuable business lessons that anyone can learn and benefit from.

Lyft Stock Versus Uber Stock: Which Ride Sharer Wins Out?

By Josh Enomoto, InvestorPlace Contributor

Though ride sharing is a massive phenomenon, both Uber and Lyft stock have printed much red ink. Subsequently, the underlying respective companies are addressing the profitability issue in different ways. Still, Lyft may stand out because of its positive vibes.

An Earnings Disappointment Sets Up a Discount for Cisco Stock Investors

By Josh Enomoto, InvestorPlace Contributor

Fiscal Q2 results sent Cisco stock tumbling as revenue trends continued down. Still, outside factors tamping shares will eventually fade, leaving a very solid name at an attractive discount.

Why Amarin Stock Is Getting No Love Early in 2020

By Josh Enomoto, InvestorPlace Contributor

Despite substantial attention on Amarin stock due to the underlying company’s Vascepa drug receiving FDA approval, shares haven’t looked great in 2020. Is this a discounted opportunity or a sign to stay away?

Load More